Atossa Genetics: Potential Breakthrough in Breast Cancer?
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
- Latest
- Trending
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
TD Cowen increases price target for HCA Holdings, expects strong performance & market share growth. Positive outlook for the healthcare ...
Goldman Sachs reaffirms Buy rating on ASML Holding NV, expects strong growth in 2025. ASML's impressive order intake and competitive ...
Emeren Group has launched a $10M accelerated stock repurchase program, aiming to increase shareholder value and strengthen its position in ...
Diamondback Energy and Endeavor Energy Resources are set to merge in a $26 billion deal, creating a dominant player in ...
New Jersey considers expanding family leave protections to workers at small companies, guaranteeing employment reinstatement for workers in companies with ...
Goldman Sachs reveals that the European version of the Magnificent 7, known as GRANOLAS, trades at a 30% discount. These ...
India's top IT companies are set to benefit as customers phase out legacy applications. With their expertise in modernization and ...
WA.Technology and Supabets have announced a strategic partnership to expand their presence in the African market. This collaboration aims to ...
The legal situation surrounding Elon Musk puts pressure on Dogecoin's market performance, leading to a decrease in value and uncertainty ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.